Using the TCGA database for bioinformatics analysis, we found that in the unmatched samples, the expression of TGFA was higher in the following malignancies than in normal tissues: bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma and endometrial adenocarcinoma (CESC), cholangiocarcinoma (CHOL), oesophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma cancer (LUSC), gastric adenocarcinoma (STAD), thyroid adenocarcinoma (THCA) and endometrial cancer (UCEC). Here, TGFA is linked to bladder transitional cell carcinoma.